86718-01-6

Usage

Uses

Used in Chemical Research:
Methyl imidazo[1,2-a]pyridine-7-carboxylate is used as a research compound for studying its chemical properties and reactions. It is typically utilized in laboratory settings to explore its behavior and potential interactions with other compounds.
Used in Pure Chemistry Research:
Methyl imidazo[1,2-a]pyridine-7-carboxylate is used as a subject of pure chemistry research, where its structure, synthesis, and reactivity are investigated. Methyl imidazo[1,2-a]pyridine-7-carboxylate's potential applications in fields such as pharmaceuticals or materials science are not well-documented, indicating that its primary interest lies in the realm of fundamental scientific inquiry.

Upstream product

• 6937-03-7 methyl 2-aminoisonicotinate 
• 67-56-1 methanol 
• 648423-85-2 imidazo[1,2-a]pyridine-7-carboxylic acid 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 107-20-0 2-chloroethanal 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 

Downstream Products

• 1009378-93-1 methyl 3-iodoimidazo[1,2-a]pyridine-7-carboxylate 
• 136117-77-6 1-imidazo[1,2-a]pyridin-7-ylpropan-2-one 
• 136117-75-4 7-(2-nitro-1-propenyl)imidazo<1,2-a>pyridine 
• 136117-86-7 (Z)-4-Dimethylamino-3-imidazo[1,2-a]pyridin-7-yl-but-3-en-2-one 
• 136117-90-3 5-Imidazo[1,2-a]pyridin-7-yl-6-methyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile 
• 648423-85-2 imidazo[1,2-a]pyridine-7-carboxylic acid 
• 1019258-66-2 methyl 3-(hydroxymethyl)imidazo[1,2-a]pyridine-7-carboxylate 
• 1220708-85-9 N-butyl-5-(imidazo[1,2-a]pyridin-7-yl)-1,3,4-thiadiazol-2-amine 
• 342613-63-2 methyl 3-bromoimidazo[1,2-a]pyridine-7-carboxylate 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES

The present invention discloses compounds according to Formula (I), wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF

The present application relates to novel substituted imidazopyridine amides of the formula (I), to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular, neurological and central nervous as well as metabolic disorders.

NEW 2-AMIDOTHIADIAZOLE DERIVATIVES

New 2-amidothiadiazole derivatives having the chemical structure of formula (I) or pharmaceutically acceptable salts or N-oxides thereof as agonists of S1P1 receptors.

6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS

The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS

The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, q, A, B, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS

The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES

Compounds having formula I:where A1, A2, L, V, W, R1, R2, R3, R4 and R5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.

IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula (I) in which A, B, R1, R1a, R2, R3, R4, R5, R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1

IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES

The present invention relates to imidazopyridine and imidazopyrimidine derivatives that act as cannabinoid receptor ligands, e.g., CB2 ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

NOVEL FUSED IMIDAZOLE DERIVATIVE

The present invention relates to a compound represented by the Formula [I]: Wherein: the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A1 and A2, are each a nitrogen atom, and the like; X2, X3, X4, and X5 are all carbon atoms, or alternatively any one of X2, X3, X4, and X5 is a nitrogen atom and the rest are all carbon atoms; R1 is a hydrogen atom, or the like; R2, R3, R4, and R5, are each a hydrogen atom, or the like; R6 and R6', are each a hydrogen atom, and the like; R7 is an aryl group and the like; and R8 is an amino group or a hydroxy group, or a pharmaceutically acceptable salt or ester thereof.